Provides non-invasive cancer screening tests and diagnostics, focusing on early detection and prevention of colorectal and other cancers.
Exact Sciences Corporation specializes in providing advanced cancer screening and diagnostic test products both domestically in the United States and internationally. Central to its offerings is Cologuard, a groundbreaking non-invasive stool-based DNA screening test designed to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancerous conditions. In addition to Cologuard, Exact Sciences offers a range of diagnostic tools including Oncotype DX, a gene expression test utilized for assessing breast, prostate, and colon cancers. The company also provides Oncotype Test, a tissue-based assay that provides detailed tumor profiling to guide therapy selection for patients facing advanced, metastatic, refractory, or recurrent cancer.
Exact Sciences continues to expand its portfolio through innovative pipeline products aimed at enhancing the performance capabilities of the Cologuard test. This includes the development of blood-based and other fluid-based tests that promise to further advance cancer detection and diagnostic accuracy. With strategic license agreements in place with institutions such as the MAYO Foundation for Medical Education and Research, and collaborations with industry leaders like Hologic, Inc., Exact Sciences remains dedicated to advancing the field of cancer diagnostics through cutting-edge technology and research.
Founded in 1995 and headquartered in Madison, Wisconsin, Exact Sciences is committed to improving patient outcomes by providing state-of-the-art screening and diagnostic solutions. The company's comprehensive approach to cancer detection underscores its mission to reduce the global burden of cancer through early detection and precise diagnostic tools.